Loading…
← CockpitCompetitor Analysis › CTMX CytomX Therapeutics, Inc.Open in the cockpit ↗

CytomX Therapeutics, Inc.CTMXCompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major
Momentum laggard 9
Mkt cap
$410M
US dollars, full cap
Free float
81%
of shares outstanding
$/day
$11.3M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 16.1%
Hurdle
n/a
no reverse DCF
Next earnings
98 days
24 Feb 2027
Close · USD$1.88
1D-3.1%
1W-11.7%
1M-25.1%
3M-42.9%
6M-49.5%
YTD-55.9%
1Y-47.0%
ATR %9.3%
Beta1.50
52w lowhigh77.1% off high

What CytomX Therapeutics does

Employees: 69

CytomX Therapeutics at a glance

Size CytomX Therapeutics (CTMX) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $410M, the 2815th largest of 3,085 United States companies the cockpit tracks. Shares closed at $1.88 on 18 Nov 2026.

Performance Over six months the shares fell 49.5%, against -16.7% for the median peer and -2.2% for the United States market (cap-weighted) — 3rd lowest of 21 in its peer set.

Growth Revenue fell 87.7% over the last twelve months (peer median +7.2%); the operating margin is -676.5% (peer median 1.9%).

Valuation It trades at 4.7× enterprise value to sales against a peer median of 3.3× (9th most expensive of 19).

Short interest Short interest is 20.8% of the free float (30 Oct 2026).

Next results Next results expected around 24 Feb 2027 (exchange calendar; dates can move).

Relative performance

608010021 May 202621 Aug 202618 Nov 2026Peer median 84CTMX 50
Six months, rebased to 100: CytomX Therapeutics against the median of its 20 peers (local-currency closes).

CytomX Therapeutics financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$14.0M$76.2M$138M$101M$53.2M
Revenue growth—-45%+36%+90%—
Gross profit$12.8M$74.8M$136M$99.0M$47.3M
EBITDA-$93.7M-$18.2M$26.8M-$4.31M-$87.8M
Net income-$85.4M-$17.4M$31.9M-$569,000-$99.3M
Free cash flow-$51.0M-$75.8M-$86.5M-$56.9M-$113M
Capital expenditure$790,000$220,000$310,000$840,000$1.74M
Total debt$4.39M$4.24M$9.38M$14.0M$18.1M

Quarterly statements and history in the cockpit →

CytomX Therapeutics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%-25%0%+25%+50%-20%0%RZLT78710028646535000931002581002728603139TVGN3006360010606010894114048410OVIDZOTA600613219A002923PHATCTMX6-month return →1-month return →
Up and to the right = strong over both horizons. CytomX Therapeutics is the large dot.

Fundamentals: revenue growth against valuation

0%+2,000%+4,000%+6,000%0×200×400×78710028646535000931048410OVID219ACTMXRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. CytomX Therapeutics is the large dot.

CytomX Therapeutics competitors and peer comparison

How CytomX Therapeutics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

CytomX Therapeutics against its 20 peers (data as of 18 Nov 2026)
MeasureCTMXPeer medianRank in peer set
1-month return-25.1%-9.8%2nd lowest of 21
6-month return-49.5%-16.7%3rd lowest of 21
Distance from 52-week high-77.1%-44.1%lowest of 21
Revenue growth (TTM)-87.7%+7.2%lowest of 19
Operating margin-676.5%1.9%3rd lowest of 19
EV / Sales4.7×3.3×9th most expensive of 19

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
CytomX Therapeutics CTMXUnited States$410M-49%-88%-676%4.7×n/an/a
Rezolute RZLTUnited States$411M+32%n/an/an/an/an/a
Elixiron Immunotherapeutics (Cayman) 7871.TWOTaiwan$412M+64%+6,162%-194%119.7×n/an/a
Shaanxi Panlong Pharmaceutical 002864.SZChina$407M-15%-16%7%1.7×-3.2%+11.2%
Lumosa Therapeutics 6535.TWOTaiwan$406M-37%-25%-803%399.1×n/an/a
Beijing Centergate Technologies (Holding) 000931.SZChina$406M-18%-16%2%1.9×9.2%+6.7%
Shandong Sinobioway Biomedicine 002581.SZChina$405M-24%+91%-65%7.9×n/an/a
Teyi Pharmaceutical 002728.SZChina$419M-12%-7%7%3.2×24.4%+8.0%
Shaanxi Kanghui Pharmaceutical Co 603139.SSChina$421M-31%+1%-39%7.1×n/an/a
Tevogen TVGNUnited States$422M-38%n/an/an/an/an/a
Jiangxi Synergy Pharmaceutical 300636.SZChina$398M-13%-3%2%3.4×14.9%+13.7%
JW Pharmaceutical 001060.KSSouth Korea$423M-26%+9%13%0.7×-15.4%+7.2%
Beijing Foyou Pharma 601089.SSChina$423M-27%+5%10%0.2×n/an/a
Synmosa Biopharma 4114.TWOTaiwan$423M-1%+21%10%2.2×5.4%+15.3%
Hyundai Bioscience 048410.KSSouth Korea$424M-50%+78%-580%164.0×n/an/a
Ovid Therapeutics OVIDUnited States$427M-5%-78%-4,700%208.3×n/an/a
Zota Health Care ZOTA.NSIndia$427M+9%+69%-16%6.2×n/an/a
Shanghai Shenqi Pharmaceutical Investment Management 600613.SSChina$427M+4%-4%3%1.2×10.6%+1.4%
Heartseed 219A.TJapan$392M+53%+197%9%21.9×46.5%+73.2%
Zhuhai Rundu Pharmaceutical 002923.SZChina$430M-30%+14%5%2.2×1.4%-1.3%
Phathom Pharmaceuticals PHATUnited States$431M-55%+87%-9%2.9×n/an/a

Questions

Which companies are CytomX Therapeutics's closest peers?
The cockpit's peer set: Rezolute (RZLT), Elixiron Immunotherapeutics (Cayman) (7871.TWO), Shaanxi Panlong Pharmaceutical (002864.SZ), Lumosa Therapeutics (6535.TWO), Beijing Centergate Technologies (Holding) (000931.SZ), Shandong Sinobioway Biomedicine (002581.SZ), Teyi Pharmaceutical (002728.SZ), Shaanxi Kanghui Pharmaceutical Co (603139.SS).
Is CytomX Therapeutics expensive compared with its peers?
On ev / sales it trades at 4.7× against a peer median of 3.3×, 9th most expensive of 19 in its peer set.
How has CytomX Therapeutics stock performed?
Over six months to 18 Nov 2026 the shares returned -49.5% against -16.7% for the median peer; over one year -47.0%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.